Allogene Therapeutics, Inc.
NASDAQ:ALLO
Overview | Financials
Company Name | Allogene Therapeutics, Inc. |
Symbol | ALLO |
Currency | USD |
Price | 2.19 |
Market Cap | 459,181,680 |
Dividend Yield | 0% |
52-week-range | 1.78 - 5.78 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. David D. Chang M.D., Ph.D. |
Website | https://www.allogene.com |
An error occurred while fetching data.
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD